Log in

NASDAQ:SNSS - Sunesis Pharmaceuticals Stock Price, Forecast & News

$0.35
-0.03 (-7.89 %)
(As of 12/6/2019 03:17 AM ET)
Today's Range
$0.19
Now: $0.35
$0.38
50-Day Range
$0.35
MA: $0.50
$0.66
52-Week Range
$0.19
Now: $0.35
$1.77
Volume28.08 million shs
Average Volume1.02 million shs
Market Capitalization$38.96 million
P/E RatioN/A
Dividend YieldN/A
Beta2.67
Sunesis Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, a topoisomerase 2 inhibitor, which completed a Phase 3 trial in patients with relapsed or refractory acute myeloid leukemia. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:SNSS
CUSIP86732860
Phone650-266-3500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$240,000.00
Book Value($0.45) per share

Profitability

Net Income$-26,610,000.00

Miscellaneous

Employees29
Market Cap$38.96 million
Next Earnings Date3/5/2020 (Estimated)
OptionableOptionable

Receive SNSS News and Ratings via Email

Sign-up to receive the latest news and ratings for SNSS and its competitors with MarketBeat's FREE daily newsletter.


Sunesis Pharmaceuticals (NASDAQ:SNSS) Frequently Asked Questions

What is Sunesis Pharmaceuticals' stock symbol?

Sunesis Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNSS."

How were Sunesis Pharmaceuticals' earnings last quarter?

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) announced its quarterly earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.10) by $0.04. View Sunesis Pharmaceuticals' Earnings History.

When is Sunesis Pharmaceuticals' next earnings date?

Sunesis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Sunesis Pharmaceuticals.

What price target have analysts set for SNSS?

3 brokerages have issued 12-month price targets for Sunesis Pharmaceuticals' stock. Their forecasts range from $1.50 to $6.00. On average, they anticipate Sunesis Pharmaceuticals' stock price to reach $3.75 in the next twelve months. This suggests a possible upside of 971.4% from the stock's current price. View Analyst Price Targets for Sunesis Pharmaceuticals.

What is the consensus analysts' recommendation for Sunesis Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sunesis Pharmaceuticals in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Sunesis Pharmaceuticals.

What are Wall Street analysts saying about Sunesis Pharmaceuticals stock?

Here are some recent quotes from research analysts about Sunesis Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. It has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. It is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. " (11/16/2019)
  • 2. HC Wainwright analysts commented, "Our $267 price target is derived from a risk-adjusted (does not include CMT or Sanfilippo A) DCF analysis and is based on: beta of 1.79, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 8.7%, and tax rate of 15% beginning in FY 2024." (6/17/2019)

Has Sunesis Pharmaceuticals been receiving favorable news coverage?

News stories about SNSS stock have trended somewhat positive on Friday, InfoTrie reports. The research group scores the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Sunesis Pharmaceuticals earned a media sentiment score of 0.7 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Sunesis Pharmaceuticals.

Are investors shorting Sunesis Pharmaceuticals?

Sunesis Pharmaceuticals saw a increase in short interest during the month of November. As of November 15th, there was short interest totalling 1,130,000 shares, an increase of 408.3% from the October 31st total of 222,300 shares. Based on an average trading volume of 556,700 shares, the days-to-cover ratio is presently 2.0 days. Approximately 1.8% of the shares of the stock are sold short. View Sunesis Pharmaceuticals' Current Options Chain.

Who are some of Sunesis Pharmaceuticals' key competitors?

What other stocks do shareholders of Sunesis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sunesis Pharmaceuticals investors own include SLS International (SLS), QUALCOMM (QCOM), NVIDIA (NVDA), Exelixis (EXEL), Micron Technology (MU), Novavax (NVAX), Progenics Pharmaceuticals (PGNX), Rigel Pharmaceuticals (RIGL), Sangamo Therapeutics (SGMO) and Conatus Pharmaceuticals (CNAT).

Who are Sunesis Pharmaceuticals' key executives?

Sunesis Pharmaceuticals' management team includes the folowing people:
  • Mr. Dayton Misfeldt, Interim CEO & Director (Age 45)
  • Mr. William P. Quinn, Sr. VP of Fin. & Corp. Devel. and CFO (Age 48)
  • Mr. Daniel N. Swisher Jr., Strategic Advisor (Age 56)
  • Mr. Gene C. Jamieson, VP of Technical Operations
  • Dr. Judith A. Fox, Chief Scientific Officer

Who are Sunesis Pharmaceuticals' major shareholders?

Sunesis Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Point72 Asset Management L.P. (2.69%) and Millennium Management LLC (0.38%). Company insiders that own Sunesis Pharmaceuticals stock include Aisling Capital Iv, Lp and William P Quinn. View Institutional Ownership Trends for Sunesis Pharmaceuticals.

Which major investors are buying Sunesis Pharmaceuticals stock?

SNSS stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P. and Millennium Management LLC. Company insiders that have bought Sunesis Pharmaceuticals stock in the last two years include Aisling Capital Iv, Lp and William P Quinn. View Insider Buying and Selling for Sunesis Pharmaceuticals.

How do I buy shares of Sunesis Pharmaceuticals?

Shares of SNSS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Sunesis Pharmaceuticals' stock price today?

One share of SNSS stock can currently be purchased for approximately $0.35.

How big of a company is Sunesis Pharmaceuticals?

Sunesis Pharmaceuticals has a market capitalization of $38.96 million and generates $240,000.00 in revenue each year. The biopharmaceutical company earns $-26,610,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis. Sunesis Pharmaceuticals employs 29 workers across the globe.View Additional Information About Sunesis Pharmaceuticals.

What is Sunesis Pharmaceuticals' official website?

The official website for Sunesis Pharmaceuticals is http://www.sunesis.com/.

How can I contact Sunesis Pharmaceuticals?

Sunesis Pharmaceuticals' mailing address is 395 OYSTER POINT BOULEVARD SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-266-3500 or via email at [email protected]


MarketBeat Community Rating for Sunesis Pharmaceuticals (NASDAQ SNSS)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  375 (Vote Outperform)
Underperform Votes:  406 (Vote Underperform)
Total Votes:  781
MarketBeat's community ratings are surveys of what our community members think about Sunesis Pharmaceuticals and other stocks. Vote "Outperform" if you believe SNSS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNSS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/6/2019 by MarketBeat.com Staff

Featured Article: How mutual funds make money

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel